Suppr超能文献

评估新辅助化疗后前哨淋巴结活检阴性的临床淋巴结分期为2期和3期乳腺癌患者的生存结局:单纯前哨淋巴结活检与腋窝淋巴结清扫术的比较

Evaluating the survival outcomes in clinical node stage 2 and 3 breast cancer patients with negative sentinel lymph node biopsy after neoadjuvant chemotherapy: sentinel lymph node biopsy alone vs. axillary lymph node dissection.

作者信息

Shin Eunju, Yoo Tae-Kyung, Kim Jisun, Chung Il Yong, Ko Beom Seok, Kim Hee Jeong, Lee Jong Won, Son Byung Ho, Lee Sae Byul

机构信息

Division of Breast Surgery, Department of Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.

出版信息

Front Oncol. 2025 May 20;15:1563586. doi: 10.3389/fonc.2025.1563586. eCollection 2025.

Abstract

PURPOSE

With the advancement of neoadjuvant chemotherapy (NAC), the reliance on surgical removal of axillary for high-risk breast cancer is diminishing. However, there is a lack of data on the oncologic safety of sentinel lymph node biopsy (SNB) alone in patients with clinical node stages 2 and 3 who show a favorable response to NAC. This study aims to compare the oncologic outcomes of SNB alone versus SNB combined with axillary lymph node dissection (ALND) in this patient cohort.

METHODS

Conducted at Asan Medical Center, this retrospective study analyzed data from breast cancer patients treated with NAC between 2008 and 2021. Propensity score matching (PSM) was employed to compare patients based on treatment approach. SNB was performed on patients demonstrating significant response to NAC with minimal nodal involvement and ALND was reserved for cases with negative SNB results, as determined by the operating surgeon. The study evaluated oncologic safety by comparing axillary recurrence-free survival (ARFS), regional recurrence-free survival (RRFS), and overall survival (OS) across surgical methods.

RESULTS

Over a median follow-up of 44 months, the overall axillary recurrence rate was 2.3%, and the univariate and multivariate analyses showed no statistically significant differences in ARFS, RRFS, and OS between the groups. Propensity score-matched analysis further confirmed the absence of significant differences in 5-year ARFS, RRFS, and OS outcomes between the SNB-only and ALND groups.

CONCLUSIONS

This study demonstrates that performing sentinel node biopsy alone is feasible in patients with clinical node stage 2-3 after neoadjuvant chemotherapy. The findings suggest the potential for de-escalation of axillary management in these patients, which could be further explored in follow-up studies.

摘要

目的

随着新辅助化疗(NAC)的进展,高危乳腺癌对腋窝淋巴结清扫术的依赖程度正在降低。然而,对于临床分期为2期和3期且对NAC反应良好的患者,单独进行前哨淋巴结活检(SNB)的肿瘤学安全性缺乏相关数据。本研究旨在比较该患者群体中单独进行SNB与SNB联合腋窝淋巴结清扫术(ALND)的肿瘤学结局。

方法

本回顾性研究在峨山医学中心进行,分析了2008年至2021年接受NAC治疗的乳腺癌患者的数据。采用倾向评分匹配(PSM)根据治疗方法对患者进行比较。对NAC反应显著且淋巴结受累最少的患者进行SNB,而对于手术医生判定SNB结果为阴性的病例则进行ALND。该研究通过比较不同手术方法的腋窝无复发生存率(ARFS)、区域无复发生存率(RRFS)和总生存率(OS)来评估肿瘤学安全性。

结果

在中位随访44个月期间,总体腋窝复发率为2.3%,单因素和多因素分析显示两组之间在ARFS、RRFS和OS方面无统计学显著差异。倾向评分匹配分析进一步证实,仅行SNB组和ALND组在5年ARFS、RRFS和OS结局方面无显著差异。

结论

本研究表明,新辅助化疗后临床分期为2 - 3期的患者单独进行前哨淋巴结活检是可行的。研究结果提示在这些患者中降低腋窝处理强度的可能性,这可在后续研究中进一步探索。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4659/12129956/08b8f57b7e48/fonc-15-1563586-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验